Recent trends show a significant shift in clinical trial locations, particularly for U.S. and UK biopharma companies, as they increasingly turn to overseas sites, especially in China, to expedite trial timelines.
The FDA's acceptance of foreign clinical data has led to a growing number of trials being conducted outside the U.S., with over 50% of registered clinical trials as of February being based solely overseas. This is a stark contrast to the 29% of trials conducted exclusively within the U.S. The appeal of conducting trials in China is largely due to lower costs and the ability to accelerate timelines through efficient patient recruitment and execution.
Notably, a report highlights that the duration from early discovery to investigational new drug approval is significantly reduced in China, with timelines being 50% to 70% shorter than in other regions. Furthermore, recruitment for later-stage trials is notably faster in China, with rates two to five times quicker than in the U.S., attributed to the presence of large patient populations and well-equipped trial sites.
This trend suggests that, unless there are regulatory changes, biopharma companies will likely continue to pursue licensing agreements and expand their R&D efforts in China and other international locations to optimize costs and enhance the speed of clinical development.